New Formula (I) compounds are disclosed having NR2B selective NMDA receptor antagonist
activity:
##STR1##
wherein
- one of the neighboring R1, R2, R3 and
R4 groups is OH or NH2 and the others are each hydrogen , or
- two of the neighboring R1, R2 R3 and
R4 groups in given case together with one or more identical or different
additional hetero atom and -CH and/or -CH2- groups forms a 5-6
membered homo- or heterocyclic ring, preferably pyrrole, pyrazole, imidazole, oxazole,
oxo-oxazolidine, or 3-oxo-1,4-oxazine ring, and the other two of R1,
R2, R3 and R4 groups are hydrogen atoms,
- R5 and R6 together with the nitrogen between them
form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted
by hydroxy group, and/or in given case phenyl or phenoxy, phenyl-(C1-C4
alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4
alkyl), anilino, phenyl-(C1-C4 alkylamino), [phenyl-(C1-C4
alkyl)]-amino, benzoyl, hydroxy-diphenylmethyl, C1-C4 alkoxycarbonyl-phenoxymethyl
or benzhydrylidene group, optionally substituted on the aromatic ring by one or
more halogen atom, cyano or hydroxy group, C1-C4 alkyl or
C1-C4 alkoxy group,
- X is independently oxygen, -NH- or a CH2 group,
- Y is independently a nitrogen atom or a -CH- group, and the salts thereof
formed with acids and bases.
|
|
|
